Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Skin Rash

Skin Rash

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Skin Rash

3 trials tracked for Skin Rash.

3Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 2 Other / NA 1
  1. Phase 2 Tetracycline as a Prophylaxis for Rash in Patients With NSCLC Receiving Treatment With BIBW2992 (Afatinib) Completed
  2. Phase 2 Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy Completed
  3. N/A Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors Completed

Showing the 3 most-cited and recently-updated of 3 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Honeysuckle therapy improves clinical management of EGFR inhibitor-related skin rash in patients
Drug Pipeline Meta-analysis
Honeysuckle therapy improves clinical management of EGFR inhibitor-related skin rash in patients Honeysuckle Therapy May Help Manage Skin Rashes from EGFR Inhibitors
This meta-analysis of 534 patients evaluated honeysuckle therapy for managing EGFR inhibitor-related skin rash. The analysis found that hone…
Honeysuckle therapy may delay the onset and reduce the severity of skin rashes caused by certain cancer treatments like EGFR inhibitors.
Frontiers Sep 14, 2026
PD-1 and PD-L1 inhibitors increase the risk of skin rash in cancer patients
Oncology Meta-analysis
PD-1 and PD-L1 inhibitors increase the risk of skin rash in cancer patients Immunotherapy drugs increase rash risks for cancer patients
This meta-analysis evaluated the risk of developing rashes in cancer patients treated with PD-1 or PD-L1 inhibitors, both alone and in combi…
New data shows that certain immunotherapy drugs used to treat cancer significantly increase the risk of developing skin rashes.
NEJM Aug 19, 2026